Please assess the completion status of the following clinical trial:

Trial Title: Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All adult subjects over the age of 18 with chronic pain\* presenting to the emergency department with exacerbation of their chronic pain as their primary complaint~* Subjects who are willing and able to provide informed consent. \*Chronic pain defined as greater \> 3 months of symptoms and an initial VAS pain score \> 70~Exclusion Criteria:~* History of overt psychosis, severe hypertension as defined by Systolic Blood Pressure \> 180 mm Hg or Diastolic Blood Pressure \>110 mm Hg, unstable angina, Coronary Artery Disease, Congestive Heart Failure, porphyrias, thyroid disease, seizure disorder, inability to provide informed consent: dementia, non-English/Spanish speakers, subjects in custody, suicidal, or clinically intoxicated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo controlled arm
- very low dose ketamine (Type: EXPERIMENTAL): 0.25 mg/kg of sub-dissociative ketamine as an experimental arm
- low dose ketamine (Type: EXPERIMENTAL): 0.50 mg/kg of sub-dissociative ketamine as an experimental arm

Based on this trial design, predict the completion outcome and termination type (if applicable).